SCHEMBL6692816

SCHEMBL6692816

OCCC[C@@H](O)[C@H](O)CO

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TDP1 Q9NUW8 2/20 0.40
THRB P10828 1/20 0.38
CYP2D6 P10635 2/20 0.34
SPHK1 Q9NYA1 1/20 0.34
GMNN O75496 1/20 0.34
POLB P06746 1/20 0.34
THPO P40225 1/20 0.34
MTOR P42345 1/20 0.34
BLM P54132 1/20 0.34
KDM4E B2RXH2 1/20 0.34
TP53 P04637 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 1/20 0.34
CETP P11597 1/20 0.34
HTT P42858 1/20 0.34
UBE2N P61088 1/20 0.34
PTPN1 P18031 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8750054 1.00 LMNA (0.42) LMNAL3MBTL1TDP1THRBCYP2D6
SCHEMBL12684655 1.00 LMNA (0.42) LMNAL3MBTL1TDP1THRBCYP2D6
SCHEMBL29920 1.00 LMNA (0.42) LMNAL3MBTL1TDP1THRBCYP2D6
SCHEMBL21885889 1.00 LMNA (0.42) LMNAL3MBTL1TDP1THRBCYP2D6
SCHEMBL151903 0.91 LMNA (0.40) LMNAL3MBTL1TDP1THRBCYP2D6
SCHEMBL1687120 0.90 THRB (0.37) LMNAL3MBTL1TDP1THRBCYP2D6
SCHEMBL891846 0.88 LMNA (0.41) LMNAL3MBTL1TDP1THRBCYP2D6
SCHEMBL6448213 0.88 LMNA (0.41) LMNAL3MBTL1TDP1THRBCYP2D6
SCHEMBL2985499 0.88 LMNA (0.41) LMNAL3MBTL1TDP1THRBCYP2D6
SCHEMBL3168782 0.88 LMNA (0.41) LMNAL3MBTL1TDP1THRBCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242569-A1 PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS THE SCRIPPS RESEARCH INSTITUTE 2023-08-03 US disclosed
US-20230212204-A1 REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS THE SCRIPPS RESEARCH INSTITUTE 2023-07-06 US disclosed
US-11613554-B2 Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2023-03-28 US disclosed
US-20220143064-A1 TAU ANTISENSE OLIGOMERS AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2022-05-12 US disclosed
WO-2021242755-A1 LOW DISHING OXIDE CMP POLISHING COMPOSITIONS FOR SHALLOW TRENCH ISOLATION APPLICATIONS AND METHODS OF MAKING THEREOF VERSUM MATERIALS US, LLC (US) 2021-12-02 WO disclosed
US-11077132-B2 Tau antisense oligomers and uses thereof F. HOFFMANN-LA ROCHE AG (CH) 2021-08-03 US disclosed
US-10799523-B2 Tau antisense oligomers and uses thereof F. HOFFMANN-LA ROCHE AG (CH) 2020-10-13 US disclosed
EP-3653712-A1 TAU ANTISENSE OLIGOMERS AND USES THEREOF H. Hoffnabb-La Roche Ag (CH) 2020-05-20 EP disclosed
US-20190322694-A1 NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS THE SCRIPPS RESEARCH INSTITUTE 2019-10-24 US disclosed
US-20180161356-A1 TAU ANTISENSE OLIGOMERS AND USES THEREOF ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) 2018-06-14 US disclosed
US-9394270-B2 Cytotoxin compounds and methods of isolation UNIVERSITY OF SOUTH FLORIDA (US) 2016-07-19 US disclosed
US-20140194495-A1 CYTOTOXIN COMPOUNDS AND METHODS OF ISOLATION THE UAB RESEARCH FOUNDATION (US) 2014-07-10 US disclosed
US-20140194495-A1 CYTOTOXIN COMPOUNDS AND METHODS OF ISOLATION THE UAB RESEARCH FOUNDATION (US) 2014-07-10 US disclosed
US-8669376-B2 Cytotoxin compounds and methods of isolation UNIVERSITY OF SOUTH FLORIDA (US) 2014-03-11 US disclosed
US-8669376-B2 Cytotoxin compounds and methods of isolation UNIVERSITY OF SOUTH FLORIDA (US) 2014-03-11 US disclosed
US-20090192215-A1 Cytotoxin Compounds and Methods of Isolation UNIVERSITY OF SOUTH FLORIDA (US) 2009-07-30 US disclosed
US-20090192215-A1 Cytotoxin Compounds and Methods of Isolation UNIVERSITY OF SOUTH FLORIDA (US) 2009-07-30 US disclosed
WO-2007035734-A2 CYTOTOXIN COMPOUNDS AND METHODS OF ISOLATION UNIVERSITY OF SOUTH FLORIDA (US) 2007-03-29 WO disclosed
US-20040033967-A1 Alkylated hexitol nucleoside analogues and oligomers thereof K.U.LEUVEN RESEARCH AND DEVELOPMENT (BE) 2004-02-19 US disclosed
WO-2002018406-A1 ALKYLATED HEXITOL NUCLEOSIDE ANALOGUES AND OLIGOMERS THEREOF K.U.LEUVEN RESEARCH AND DEVELOPMENT (BE) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161356-A1 TAU ANTISENSE OLIGOMERS AND USES THEREOF MAPT, FUS, TARDBP LMNA 2316/4885L3MBTL1 308/4885TDP1 152/4885
US-20230242569-A1 PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS PPIP5K2, INPP5B, PTMS LMNA 2930/4885L3MBTL1 2573/4885TDP1 2235/4885
US-20140194495-A1 CYTOTOXIN COMPOUNDS AND METHODS OF ISOLATION XPA, ANXA5, ST14 LMNA 524/4885L3MBTL1 1728/4885TDP1 2201/4885
US-20090192215-A1 Cytotoxin Compounds and Methods of Isolation XPA, ANXA5, ST14 LMNA 524/4885L3MBTL1 1728/4885TDP1 2201/4885
US-20040033967-A1 Alkylated hexitol nucleoside analogues and oligomers thereof DERA, HEXA, HEXB LMNA 1261/4885L3MBTL1 745/4885TDP1 1542/4885
US-10799523-B2 Tau antisense oligomers and uses thereof MAPT, FUS, TARDBP LMNA 2316/4885L3MBTL1 308/4885TDP1 152/4885
US-20220143064-A1 TAU ANTISENSE OLIGOMERS AND USES THEREOF MAPT, FUS, TARDBP LMNA 2316/4885L3MBTL1 308/4885TDP1 152/4885
US-11613554-B2 Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds PPIP5K2, INPP5B, PTMS LMNA 2930/4885L3MBTL1 2573/4885TDP1 2235/4885
US-11077132-B2 Tau antisense oligomers and uses thereof MAPT, FUS, TARDBP LMNA 2316/4885L3MBTL1 308/4885TDP1 152/4885
US-20190322694-A1 NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS PPIP5K2, INPP5B, PTMS LMNA 3123/4885L3MBTL1 2862/4885TDP1 2209/4885
US-20230212204-A1 REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS PNKP, POLL, RNGTT LMNA 3270/4885L3MBTL1 1222/4885TDP1 2206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.